Latest News

  • Photocure ASA – Private placement successfully placed

    NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

    27 Apr 2020
  • Photocure ASA - Contemplated Private Placement

    NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

    27 Apr 2020
  • PHOTOCURE REGAINS WORLDWIDE RIGHTS OF HEXVIX

    HIGHLIGHTS

    • Photocure has reached an agreement with Ipsen to regain rights for the sales and marketing of Hexvix® in Europe
    • The transaction is expected to be EBITDA accretive from FY 2021
    • Ipsen achieved Hexvix 2019 sales of EUR 18.7 million and Photocure sees significant growth opportunities in Europe
    27 Apr 2020
  • Photocure – Employee incentive program

    With reference to the senior management share option program in Photocure ASA ("Photocure" or "Company"), on 7 April 2020 the Board of Directors in Photocure resolved the issue of in total 500,000 share options for 2019.

    08 Apr 2020
  • Photocure ASA – Annual accounts 2019

    Oslo, 8 April 2020: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2019.

    08 Apr 2020
  • Photocure ASA: Market update #2

    Oslo, Norway, 7 April 2020: The Board of Directors and Management of Photocure ASA (OSE:PHO) follow the COVID-19 situation closely and have implemented strict measures to ensure the safety of patients, customers, employees and business partners while maintaining an uninterrupted level of service and supply. The company today provides the second COVID-19 Oslo Stock Exchange notification to ensure updated and transparent stakeholder information.

    07 Apr 2020
  • Photocure ASA: Market update

    Oslo, Norway, 19 March 2020: The management of Photocure ASA (OSE:PHO) is following the Covid-19 situation closely and has implemented strict measures to ensure the safety of patients, customers, employees and business partners while maintaining an uninterrupted level of service and supply.

    19 Mar 2020
  • Photocure ASA: Results for the fourth quarter of 2019

    Oslo, Norway, 27 February 2020: Photocure ASA (OSE:PHO), today reported a revenue growth of 51% for the U.S. market in the fourth quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 58.8 million (Q4 2018: NOK 46.3) and a recurring EBITDA of NOK 1.6 million (NOK 1.3 million).

    27 Feb 2020
  • Photocure ASA: Invitation to fourth quarter and full year 2019 results presentation and webcast

    Photocure will present its fourth quarter report on Thursday 27 February 2020 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

    21 Feb 2020
  • Photocure announces new US patent for Hexvix

    Oslo, Norway February 14, 2020, Photocure ASA (OSE: PHO) is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 10,556,010 covering the use of Blue Light Cystoscopy (BLC®) with Hexvix as neoadjuvant* therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy.

    14 Feb 2020
  • New Fox 11 program on Blue Light Technology in Bladder Cancer

    The benefits of Blue light technology in the detection of Bladder Cancer are explained in detail on Fox News in a news topic featuring an interview with Dr. Sia Daneshmand on January 20, 2020.

    21 Jan 2020
  • Photocure ASA: Exercise of employee share options in Photocure ASA

    Oslo, Norway, 31 December 2019.

    Participants in the Photocure ASA's share option program have on 31 December 2019 exercised a total of 150,168 options. The share options are exercised at expiry on 31 December 2019 and at a strike price of NOK 32.78. Each option gives a right to receive one share in the company. The share options are described in note 7 in Photocure's annual financial statements for 2018.

    31 Dec 2019
  • Cevira® receives Fierce Innovation Award 2019

    Oslo, Norway December 19, 2019: Photocure ASA (Photocure, PHO: OSE) proudly announces that Cevira® received the prestigious Fierce Innovation Award (FIA), on December 18, 2019.

    19 Dec 2019
  • Photocure: Reduced recurrence after flexible Blue Light Cystoscopy with Hexvix® in surveillance ‒ New Publication of study results

    Use of flexible Blue Light Cystoscopy at the first follow-up after TURBT* reduced the risk of tumor recurrence by 33% compared to white light alone. The randomized controlled multi-center study that included 699 bladder cancer patients at 3 hospitals in Denmark is now published in Urology, The Gold Journal.

    19 Dec 2019
  • Photocure to present at the DNB Nordic Healthcare Conference in Oslo

    Oslo, Norway, December 6, 2019 - Photocure ASA (OSE: PHO) will be presenting at the DNB Nordic Healthcare Conference in Oslo on December 12.

    06 Dec 2019
  • Photocure to present at Nordic-American Life Science Conference in New York

    Oslo, Norway, November 29, 2019 - Photocure ASA (OSE: PHO) will be presenting at the Nordic-American Life Science Conference in New York on December 5.

    29 Nov 2019
  • Photocure: First trial demonstrating reduced recurrence after flexible Blue Light Cystoscopy with Hexvix® in surveillance

    Use of flexible Blue Light Cystoscopy at the first follow-up after TURBT* reduced the risk of tumor recurrence by 33% compared to white light alone. Randomized controlled multi-center study with 699 bladder cancer patients presented at Danish Urological Society meeting.

    18 Nov 2019
  • Photocure ASA: Results for the third quarter of 2019

    Oslo, Norway, 7 November 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 42% in local currency for the U.S. market in the third quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 51.1 million (Q3 2018: NOK 43.5) and an EBITDA of NOK 8.3 million (NOK -3.1 million). The company entered into a license agreement with Asieris for the global commercialization of Cevira® and reiterates the significant revenue growth and profit opportunities in the U.S. market.

    07 Nov 2019
  • Photocure: Cysview® reimbursement further improved from January 2020

    CMS final rule expands complexity adjustment for Hospital Outpatient from two to three procedure codes and increases the reimbursement due to the complexity adjustment for these procedures by $92 compared to 2019.

    05 Nov 2019